(12) **Translation of new European patent specification**
After opposition procedure

(11) **NO/EP 2341905 B2**

(19) NO

NORWAY

(51) Int Cl.
A61P 5/50 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.09.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.04.29
(45)	Decision of the opposition in EPO	2023.09.13
	Decision of the opposition in NIPO	2024.01.22
(86)	European Application Nr.	09812292.2
(86)	European Filing Date	2009.09.04
(87)	The European Application's Publication Date	2011.07.13
(30)	Priority	2008.09.04, US, 94381 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Amylin Pharmaceuticals, LLC, 9360 Towne Centre Drive, San Diego, CA 92121, USA AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE, USA
(72)	Inventor	HOUCHIN, Mary, L., 9809 Allenford Circle Apt. 03, Rockville MD 20850, USA LEE, Robin, H., 15612 Via Calanova, San Diego CA 92128, USA QI, Hong, c/o Amylin Pharmaceuticals Inc. 9360 Towne Centre Drive, San Diego CA 92121, USA OEHRTMAN, Greg, c/o Amylin Pharmaceuticals Inc. 9360 Towne Centre Drive, San Diego CA 92121, USA JENNINGS, Robert, N., c/o Amylin Pharmaceuticals Inc. 9360 Towne Centre Drive, San Diego CA 92121, USA COLEMAN, Scott, H., c/o Amylin Pharmaceuticals Inc. 9360 Towne Centre Drive, San Diego CA 92121, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS**

(56) References Cited:
WO-A1-2005/102293, US-A1- 2004 224 030, US-A1- 2008 146 490, WO-A2-2007/024700
JAIN R A ET AL: "Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 2, 1 September 2000 (2000-09-01), pages 257-262, XP004257199, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(00)00062-X

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. En fremstilt forblandet formulering for injeksjon som hovedsakelig består av en suspensjon av:

(i) en farmasøytisk akseptabel bærer som omfatter ett eller flere triglyserider av C_6 -C_{12} fettsyrer; og
(ii) mikrosfærer som hovedsakelig består av en poly(laktid-ko-glykolid) polymer med dispergert deri ca. 5 % (vekt/vekt) eksenatid som aktiv farmasøytisk ingrediens og ca. 2 % (vekt/vekt) sukrose; hvori forholdet mellom laktid:glykolid i polymeren er omtrent 1:1
hvori den farmasøytisk akseptable ikke-vandige bæreren består av en eller flere triglyserider av C_6 -C_{12} fettsyrer,
hvori triglyseridene omfatter 0 til 2 vekt% C_6 fettsyre, 50 til 65 vekt% C_8 fettsyre, 30 til 45 vekt% C_{10} fettsyre, og 0 til 2 vekt% C_{12} fettsyre.